CT与MRI肝脏影像报告和数据系统5类诊断肝细胞癌的性能比较:比较性研究的系统综述与Meta分析
该系统综述与Meta分析纳入7项直接比较CT与MRI的LR-5诊断肝细胞癌性能的研究,共1145个观察灶(725个HCC)。MRI的LR-5汇总敏感度高于CT(61% vs 48%,p<0.001),两者汇总特异度无统计学显著差异(CT 96% vs MRI 93%,p=0.054)。亚组分析中,细胞外对比剂增强MRI的汇总敏感度高于钆塞酸二钠增强MRI(73% vs 55%,p=0.007)。
要点
- MRI的LR-5诊断HCC汇总敏感度高于CT(61% vs 48%),特异度两者无显著差异。
- 细胞外对比剂增强MRI的LR-5敏感度高于钆塞酸二钠增强MRI(73% vs 55%)。
- LR-5的观察灶水平诊断性能受成像设备和MRI对比剂种类影响。
核心结论
- MRI的LR-5诊断HCC的汇总观察灶敏感度显著高于CT,两者汇总观察灶特异度相当;LR-5的观察灶水平性能可受成像设备和MRI对比剂影响。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和EMBASE从建库至2021年4月21日,纳入7项直接比较CT与MRI的LR-5诊断HCC性能的研究,共1145个观察灶(725个HCC),采用双变量随机效应模型计算汇总观察灶敏感度和特异度并比较配对数据。
诊断标准与关键数值
- MRI的LR-5诊断HCC汇总观察灶敏感度61%(95%CI 43-76%,I²=95%),CT为48%(95%CI 31-65%,I²=97%),p<0.001。
- CT的LR-5汇总观察灶特异度96%(95%CI 92-98%,I²=0%),MRI为93%(95%CI 88-96%,I²=16%),p=0.054。
- 细胞外对比剂增强MRI的LR-5汇总观察灶敏感度73%(95%CI 55-85%),钆塞酸二钠增强MRI为55%(95%CI 39-70%),p=0.007。
- 细胞外对比剂增强MRI的LR-5汇总观察灶特异度93%(95%CI 80-98%),钆塞酸二钠增强MRI为94%(95%CI 87-97%),p=0.884。
临床应用与阅片要点
- 尽管LI-RADS为CT或MRI提供共同诊断算法,LR-5的观察灶水平诊断性能可受成像设备和MRI对比剂种类影响。
局限性
- MRI的LR-5汇总敏感度异质性I²=95%,CT为I²=97%。
- CT的LR-5汇总特异度异质性I²=0%,MRI为I²=16%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the performance of Liver Imaging Reporting and Data System category 5 (LR-5) for diagnosing HCC between CT and MRI using comparative studies.
METHODS: The MEDLINE and EMBASE databases were searched from inception to April 21, 2021, to identify studies that directly compare the diagnostic performance of LR-5 for HCC between CT and MRI. A bivariate random-effects model was fitted to calculate the pooled per-observation sensitivity and specificity of LR-5 of each modality, and compare the pooled estimates of paired data. Subgroup analysis was performed according to the MRI contrast agent.
RESULTS: Seven studies with 1145 observations (725 HCCs) were included in the final analysis. The pooled per-observation sensitivity of LR-5 for diagnosing HCC was higher using MRI (61%; 95% confidence interval [CI], 43-76%; I2 = 95%) than CT (48%; 95% CI, 31-65%; I2 = 97%) (p < 0.001). The pooled per-observation specificities of LR-5 did not show statistically significant difference between CT (96%; 95% CI, 92-98%; I2 = 0%) and MRI (93%; 95% CI, 88-96%; I2 = 16%) (p = 0.054). In the subgroup analysis, extracellular contrast agent-enhanced MRI showed significantly higher pooled per-observation sensitivity than gadoxetic acid-enhanced MRI for diagnosing HCC (73% [95% CI, 55-85%] vs. 55% [95% CI, 39-70%]; p = 0.007), without a significant difference in specificity (93% [95% CI, 80-98%] vs. 94% [95% CI, 87-97%]; p = 0.884).
CONCLUSIONS: The LR-5 of MRI showed significantly higher pooled per-observation sensitivity than CT for diagnosing HCC. The pooled per-observation specificities of LR-5 were comparable between the two modalities.
KEY POINTS: • The pooled sensitivity of LR-5 using MRI was higher than that using CT (61% versus 48%), but the pooled specificities of LR-5 were not significantly different between CT and MRI (96% versus 93%). • Subgroup analysis according to the MRI contrast media showed a significantly higher pooled per-observation sensitivity using ECA-enhanced MRI than with EOB-enhanced MRI (73% versus 55%), and comparable specificities (93% versus 94%). • Although LI-RADS provides a common diagnostic algorithm for CT or MRI, the per-observation performance of LR-5 can be affected by the imaging modality as well as the MRI contrast agent.
引用
- Kim, Lee, Shin, et al. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. Eur Radiol. 2022. PMID: 35849177. doi:10.1007/s00330-022-08985-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。